Pyrimethamine: Difference between revisions
m (Protected "Pyrimethamine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
Gerald Chi (talk | contribs) m (Changed protection level for "Pyrimethamine" ([Edit=Allow only autoconfirmed users] (expires 18:03, 23 January 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 18:03, 23 January 2014 (UTC)))) |
(No difference)
|
Revision as of 18:03, 9 January 2014
File:Pyrimethamine.svg | |
Clinical data | |
---|---|
Pregnancy category | |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | well-absorbed |
Protein binding | 87% |
Metabolism | Hepatic |
Elimination half-life | 96 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C12H13ClN4 |
Molar mass | 248.71 g/mol |
Pyrimethamine (Daraprim®) is a medication used for protozoal infections. It is commonly used as an antimalarial drug (for both treatment and prevention), and is also used in the treatment of Toxoplasma gondii infections in immunocompromised patients, such as HIV-positive individuals.
Mechanism of action
Pyrimethamine interferes with folic acid synthesis by inhibiting the enzyme dihydrofolate reductase. Folic acid is needed for DNA and RNA synthesis in many species, including protozoa.
Mechanism of resistance
Resistance to pyrimethamine is widespread. Mutations in the gene for dihydrofolate reductase may reduce the effectiveness of pyrimethamine (PMID 15155209). These mutations decrease the binding affinity between pyrimethamine and dihydrofolate reductase by steric interactions (PMID 14711307).
Clinical use
Pyrimethamine is typically given with a sulfonamide and folinic acid:
- Sulfonamides inhibit dihydropteroate synthetase, an enzyme that participates in folic acid synthesis from para-aminobenzoic acid. Hence, sulfonamides work synergistically with pyrimethamine by blocking a different enzyme needed for folic acid synthesis.
- Folinic acid (Leucovorin) is a compound that can be converted into folic acid by the human body without relying on dihydrofolate reductase. By doing so, folinic acid reduces side effects related to folate deficiency.
Side effects
Pyrimethamine may deplete folic acid in humans, resulting in hematologic side effects associated with folate deficiency.
Side effects include:
- hypersensitivity reactions
- megaloblastic anemia
- leukopenia
- thrombocytopenia
- pancytopenia
- atrophic glossitis
- hematuria
- cardiac arrhythmias
- pulmonary eosinophilia (rare)
- hyperphenylalaninemia (particularly when used with a sulfonamide)
Contraindications
Pyrimethamine is contraindicated in patients with:
- hypersensitivity to pyrimethamine
- megaloblastic anemia - depletion of folic acid may aggravate this condition
References
External links
- Pages with script errors
- Pages with broken file links
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Antimalarial agents
- Antiprotozoal agents
- Dihydrofolate reductase inhibitors